|Systematic (IUPAC) name|
Cobimetinib (GDC-0973, XL-518) is a MEK inhibitor being developed by Exelixis and Roche. It is being studied in combination with vemurafenib to treat several cancers, including melanoma. One trial should complete in 2017. After good results in 2014 the combination has been submitted to EC and FDA for marketing approval.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|